

identification of viral epitopes is critically important to understanding immune responses to infection and vaccination, and there are currently no comparable methods besides the classic screening of vast arrays of overlapping viral peptides on blood lymphocytes. Peptide screening methods only identify possible target epitopes, but do not define which epitopes are expressed in lung tissue. The technology will be valuable for vaccine development and evaluation, and has the flexibility to allow rapid analysis of novel pandemic strains for immunogenic epitopes. The technology can be applied to other infectious diseases, cancer, and immunotoxicities.

II. Award Information/Funds Available

A. Award Amount

Only one grant award will be made in fiscal year (FY) 2012. The application budget is not limited, but it needs to reflect the actual needs of the proposed project. However, presently for FY 2012, the funds are available in the amount of \$400,000 (total cost), and are subject to change based on the availability of funds.

B. Length of Support

The maximum period is 1 year with the option of 4 more years of budget support depending on the availability of funds.

III. Paper Application, Registration, and Submission Information

To submit a paper application in response to this FOA, applicants should first review the full announcement located at <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm088761.htm>. Persons interested in applying for a grant may obtain an application at <http://grants2.nih.gov/grants/funding/phs398/phs398.html>. For all paper application submissions, the following steps are required:

- Step 1: Obtain a Dun and Bradstreet (DUNS) Number.
- Step 2: Register With Central Contractor Registration.
- Step 3: Register With Electronic Research Administration (eRA) Commons.

Steps 1 and 2, in detail, can be found at http://www07.grants.gov/applicants/organization_registration.jsp. Step 3, in detail, can be found at <https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp>. After you have followed these steps, submit paper applications to: Gladys Bohler, Grants Management Specialist (see **FOR FURTHER INFORMATION CONTACT** section of this document).

Dated: August 9, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2011-21043 Filed 8-17-11; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0002]

Dialogues in Diversifying Clinical Trials: Successful Strategies for Engaging Women and Minorities in Clinical Trials

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following Office of Women's Health and Society for Women's Health Research jointly sponsored meeting: Dialogues in Diversifying Clinical Trials: Successful Strategies for Engaging Women and Minorities in Clinical Trials. The purpose of this symposium is to facilitate the broader discussion and dissemination of innovative strategies for increasing the recruitment and retention of women and minority subpopulations into clinical trials. The overarching goal of this symposium is to use a best practices learning exchange to share information and encourage successful methods and/or model implementation within a broad research community—industry, academia, and government.

Date and Time: The meeting will be held on September 22, 2011, from 8 a.m. to 9 a.m. (registration); 9 a.m. to 5:30 p.m. (program); 5:30 p.m. to 6:30 p.m. (reception); and September 23, from 8 a.m. to 1:30 p.m.

Location: The meeting will be held at L'Enfant Plaza Hotel, 480 L'Enfant Plaza, SW., Washington, DC 20024.

Contact: Deborah Kallgren, FDA Office of Women's Health, 10903 New Hampshire Ave., Bldg. 32, Rm. 2314, Silver Spring, MD 20993-0002, 301-796-9442, Fax: 301-847-8604, e-mail: deborah.kallgren@fda.hhs.gov.

Registration: Registration is free, but seating is limited to 200. Registration will be accepted online and is available at <http://www.swhr.org> through September 16, 2011. For information regarding registration contact: Rachel Griffith, Society for Women's Health Research (SWHR), 1025 Connecticut Ave., NW., Suite 701, Washington, DC 20036, 202-496-5001, Fax: 202-833-3472, e-mail: rachel@swhr.org.

If you need special accommodations due to a disability, please contact Rachel Griffith at least 7 days in advance.

Dated: August 12, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2011-21042 Filed 8-17-11; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Secretary's Advisory Committee on Heritable Disorders in Newborns and Children; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463, codified at 5 U.S.C. App. 2), notice is hereby given of the following meeting:

Name: Secretary's Advisory Committee on Heritable Disorders in Newborns and Children.

Dates and Times: September 22, 2011, 8:30 a.m. to 5 p.m.; September 23, 2011, 8:30 a.m. to 3:30 p.m.

Place: Renaissance Washington, DC DuPont Circle Hotel, 1143 New Hampshire Avenue, NW., Washington, DC 20037.

Status: The meeting will be open to the public with attendance limited due to space availability. Participants are asked to register for the meeting by going to the registration Web site at <http://altarum.cvent.com/event/SACHDNC092011>. The registration deadline is Tuesday, September 20, 2011. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should indicate their needs on the registration website. The deadline for special accommodation requests is Friday, September 19, 2011. If there are technical problems gaining access to the Web site, please contact Maureen Ball, Meetings Coordinator, at conferences@altarum.org.

Purpose: The Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (Advisory Committee) was established by Congress to advise and guide the Secretary regarding the most appropriate application of universal newborn screening tests, technologies, policies, guidelines and programs for effectively reducing morbidity and mortality in newborns and children having (or at risk) for heritable disorders. The Advisory Committee, as authorized by Public Law 106-310, which added